Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for treatment of multiple myeloma

Chimeric antigen receptor (CAR) T-cell therapy remains limited to select centers that can carefully monitor adverse events. To broaden use of CAR T-cells in community clinics and in a frontline setting, we developed a novel CD8+ CAR T-cell product, Descartes-08, with predictable pharmacokinetics for...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Leukemia
Päätekijät: Lin, Liang, Cho, Shih-Feng, Xing, Lijie, Wen, Kenneth, Li, Yuyin, Yu, Tengteng, Hsieh, Phillip A., Chen, Hailin, Kurtoglu, Metin, Zhang, Yi, Stewart, C Andrew, Munshi, Nikhil, Anderson, Kenneth C, Tai, Yu-Tzu
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7785573/
https://ncbi.nlm.nih.gov/pubmed/32632095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0951-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia